Introduction to ESG in Pharma
In the dynamic pharmaceutical sector, where innovation and regulatory compliance have long been the pillars of success, a new disruptive force is emerging: Environmental, Social, and Governance (ESG) principles. ESG has progressed from a business buzzword to a regulatory requirement in many areas of the world, including Canada and the European Union (EU) (Brightest, 2025). The pharmaceutical business, which is notorious for its large environmental footprint, complicated supply chains, and sensitive social ramifications, is under increasing pressure to align its operations with global ESG standards. This article investigates the worldwide ESG norms and regulations that shape the pharmaceutical environment, as well as providing a case study to demonstrate their practical use.
What Are ESG Regulations?
ESG laws concentrate on three major components:
● Environmental (E): Waste management, carbon footprint, energy use, and influence on biodiversity.
● Social (S): Worker rights, health and safety, community involvement, and fair access to medications.
● Governance (G): Board diversity, anti-corruption policies, transparency, and ethical supplier management.
Countries and regions throughout the world, notably the European Union, Canada, the USA, and parts of Asia, are establishing formal ESG reporting requirements. These laws now oblige pharmaceutical firms to disclose not just their financial success, but also how they operate ethically and sustainably. Overall, ESG reporting requirements are becoming increasingly formalized across these regions, driven by growing concerns about climate change, sustainability, and corporate governance (López-Toro, 2021).
Global ESG Compliance: A Shifting Regulatory Landscape
European Union (EU)
The EU sets the standard via its Corporate Sustainability Reporting Directive (CSRD) and the EU Taxonomy Regulation, which require big corporations (including pharmaceutical companies) to report sustainability risks and their impact on people and the environment (EP, 2022). Additionally, the Green Deal and the European Chemicals Strategy for Sustainability have a direct impact on pharmaceutical production and disposal methods (ECHA, 2020).
Canada
Canada is advancing its sustainability agenda through frameworks like the Canadian Net-Zero Emissions Accountability Act, S.C. 2021, c. 22, and initiatives led by the Canadian Securities Administrators (CSA), which are developing climate-related disclosure requirements aligned with international standards such as the Task Force on Climate-related Financial Disclosures (TCFD) (Bijoux, 2021).
United States
In 2022, the US Securities and Exchange Commission (SEC) proposed regulations requiring public firms to report climate-related risks, emissions, and governance measures. However, with the start of the second Trump administration, which began on January 20, 2025, the SEC is likely to turn significantly away from ESG and toward Crypto, putting Canada at the forefront of ESG regulation in North America (Breheny, 2025).
Asia-Pacific
Countries such as Japan and South Korea are developing ESG disclosure rules using frameworks such as the TCFD and the International Sustainability Standards Board (ISSB) (IFRS, 2023). Meanwhile, China is implementing harsher environmental rules on several production industries, including medicines (Choi, 2025).
Global Reporting Standards
Organizations such as the Global Reporting Initiative (GRI) and the Sustainability Accounting Standards Board (SASB) offer standardized ESG frameworks that pharmaceutical companies are increasingly using to align with investor expectations and legal mandates (SASB, 2020).
ESG Impact Areas in Pharmaceuticals
1. Environmental Compliance
Pharmaceutical production frequently uses toxic chemicals and energy-intensive methods. Companies are increasingly under regulatory pressure to decrease emissio...
(All Rights Reserved)